{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:34:18Z","timestamp":1770489258673,"version":"3.49.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"suppl_2","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFC1200100"],"award-info":[{"award-number":["2018YFC1200100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Outstanding Talents Training Funding Project of Dongcheng District"},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2016-I2M-1\u2013014"],"award-info":[{"award-number":["2016-I2M-1\u2013014"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2016-I2M-3\u2013014"],"award-info":[{"award-number":["2016-I2M-3\u2013014"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011176","name":"Peking Union Medical College","doi-asserted-by":"publisher","award":["2017-1002-1-21"],"award-info":[{"award-number":["2017-1002-1-21"]}],"id":[{"id":"10.13039\/501100011176","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We conducted a national antimicrobial surveillance study of both gram-positive and gram-negative organisms isolated from hospitalized patients. This report presents data on antimicrobial susceptibility among 4998 organisms collected in China between 2012 and 2014.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>The minimum inhibitory concentrations (MICs) and susceptibilities of ceftaroline\/avibactam (CPA), ceftazidime\/avibactam (CZA) and a range of comparative agents were determined according to guidelines established by the Clinical and Laboratory Standards Institute (CLSI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The highest overall susceptibility levels for all Enterobacteriaceae during the study period were observed for CPA, CZA, doripenem (DOR), meropenem (MEM), and amikacin (AMK), which were all &amp;gt;90%. However, both CPT and CAZ alone and in combination with avibactam showed low activities for Acinetobacter spp., whereas CPA and CZA exhibited MIC90 values for Pseudomonas aeruginosa that were reduced by 4- and 8-fold, respectively, compared with those of CPT and CAZ. High susceptibilities of Acinetobacter spp. and P. aeruginosa to colistin and P. aeruginosa to AMK were observed. For the gram-positive strains, no significant activity changes were seen for Enterococcus, Staphylococcus, and viridans group streptococci to CPT or CAZ alone or in combination with avibactam, whereas Streptococcus pneumoniae and \u03b2-hemolytic Streptococcus showed almost 100% susceptibility to both CPT and CPA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The addition of 4 mg\/L avibactam greatly increased the activities of CPT and CAZ against most Enterobacteriaceae and P. aeruginosa isolates, whereas no significant changes were observed in Acinetobacter spp. or any of the gram-positive strains.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciy659","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T11:11:44Z","timestamp":1533640304000},"page":"S206-S216","source":"Crossref","is-referenced-by-count":16,"title":["In Vitro Activities of Ceftaroline\/Avibactam, Ceftazidime\/Avibactam, and Other Comparators Against Pathogens From Various Complicated Infections in China"],"prefix":"10.1093","volume":"67","author":[{"given":"Menglan","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Peking Union Medical College Hospital"},{"name":"Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences"},{"name":"Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Peking Union Medical College Hospital"},{"name":"Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences"},{"name":"Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yali","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Peking Union Medical College Hospital"},{"name":"Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjian","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Beijing Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingmei","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Beijing Chao-Yang Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, First Affiliated Hospital of Haerbin Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shufang","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Affiliated Haikou Hospital, Xiangya School of Medicine Central South University, Haikou Municipal People\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunsong","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Zhejiang University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Microbiology, Clinical Laboratory of Provincial Hospital affiliated to Shandong University, Jinan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiang","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital, Chongqing Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianju","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, First Affiliated Hospital, Zhenzhou University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiwen","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Peking Union Medical College Hospital"},{"name":"Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchun","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Peking Union Medical College Hospital"},{"name":"Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"2020061607332022200_CIT0001","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","article-title":"Diazabicyclooctanes (DBOs): a potent new class of non-\u03b2-lactam \u03b2-lactamase inhibitors","volume":"14","author":"Coleman","year":"2011","journal-title":"Curr Opin Microbiol"},{"key":"2020061607332022200_CIT0002","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"2020061607332022200_CIT0003","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1128\/AAC.02436-12","article-title":"Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010\u20132011","volume":"57","author":"Sader","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061607332022200_CIT0004","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dkp197","article-title":"In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases","volume":"64","author":"Stachyra","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2020061607332022200_CIT0005","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1128\/AAC.00641-09","article-title":"In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases","volume":"53","author":"Endimiani","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061607332022200_CIT0006","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061607332022200_CIT0007","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1128\/AAC.01722-10","article-title":"Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases","volume":"55","author":"Lagac\u00e9-Wiens","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061607332022200_CIT0008","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijantimicag.2011.09.012","article-title":"In vitro activity of avibactam (NXL104) in combination with \u03b2-lactams against Gram-negative bacteria, including OXA-48 \u03b2-lactamase-producing Klebsiella pneumoniae","volume":"39","author":"Akta\u015f","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2020061607332022200_CIT0009","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC beta-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"2020061607332022200_CIT0010","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020061607332022200_CIT0011","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1128\/AAC.02625-14","article-title":"Reclaiming the efficacy of \u03b2-lactam-\u03b2-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime","volume":"58","author":"Papp-Wallace","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061607332022200_CIT0012","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. CLSI Approved Standard M7","author":"Clinical and Laboratory Standards Institute","year":"2015","edition":"10"},{"key":"2020061607332022200_CIT0013","volume-title":"Performance standards for antimicrobial susceptibility testing. CLSI Supplement M100","author":"Clinical and Laboratory Standards Institute","year":"2017","edition":"27"},{"key":"2020061607332022200_CIT0014","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2018"},{"key":"2020061607332022200_CIT0015","volume-title":"Tygacil FDA prescribing information","author":"Pfizer, Inc","year":"2010"},{"key":"2020061607332022200_CIT0016","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ijantimicag.2014.12.033","article-title":"In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates","volume":"45","author":"Testa","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2020061607332022200_CIT0017","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1128\/AAC.01485-13","article-title":"In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study","volume":"57","author":"Karlowsky","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061607332022200_CIT0018","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/AAC.02429-13","article-title":"Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061607332022200_CIT0019","article-title":"Antimicrobial activity of ceftazidime NXL104 (CAZ104) tested against Gram negative organisms causing infections in medical centers from Europe (EU), Latin America (LA) and the Asia-Pacific region (APC)","author":"Sader","year":"2011"},{"key":"2020061607332022200_CIT0020","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1128\/AAC.06064-11","article-title":"In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates","volume":"56","author":"Levasseur","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061607332022200_CIT0021","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1128\/AAC.01696-10","article-title":"In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study)","volume":"55","author":"Walkty","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061607332022200_CIT0022","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1089\/sur.2013.172","article-title":"Antimicrobial activity of ceftaroline and other anti-infective agents against microbial pathogens recovered from the surgical intensive care patient population: a prevalence analysis","volume":"15","author":"Edmiston","year":"2014","journal-title":"Surg Infect (Larchmt)"},{"key":"2020061607332022200_CIT0023","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diagmicrobio.2015.01.015","article-title":"Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013","volume":"82","author":"Sader","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020061607332022200_CIT0024","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1186\/s12879-017-2873-z","article-title":"Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients","volume":"17","author":"Zhang","year":"2017","journal-title":"BMC Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/67\/suppl_2\/S206\/33393014\/ciy659.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/67\/suppl_2\/S206\/33393014\/ciy659.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T11:33:33Z","timestamp":1592307213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/67\/suppl_2\/S206\/5181267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":24,"journal-issue":{"issue":"suppl_2","published-online":{"date-parts":[[2018,11,13]]},"published-print":{"date-parts":[[2018,11,13]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy659","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12,1]]},"published":{"date-parts":[[2018,11,13]]}}}